Activity of panobinostat in combination with bortezomib and dexamethasone in advanced, proteasome inhibitor refractory multiple myeloma
Explore this paper's citation graph
Summary
The patient with relapsed multiple myeloma progressed after therapy with immunomodulatory agents, overcoming resistance to proteasome inhibitors and achieving a sustained VGPR (very good partial remission), which was consolidated with high-dose melphalan and autologous stem-cell transplantation.
- Type
- article
- Published
- 2017-07-18
- Cited by
- 0
- References
- 52
- OpenAlex
- https://openalex.org/W2738602720
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:80437668
Keywords
Bortezomib, Panobinostat, Carfilzomib, Multiple myeloma, Dexamethasone
References
- High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.
- Autologous retransplantation for patients with recurrent multiple myeloma
- Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
- Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
- Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.
- The future of autologous stem cell transplantation in myeloma.
- Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes
- In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
- Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
- Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation.
- Improved survival in multiple myeloma and the impact of novel therapies.
- CD38/CD19: a lipid raft-dependent signaling complex in human B cells.
- Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.
- Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
- PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.
- Importance of achieving a complete response in multiple myeloma, and the impact of novel agents.
- Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
Cited by
No citing papers recorded for this paper.
Related papers
- Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2
- Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
- Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma
- Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
- Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial
- Abstract 1768: Chloroquine potentiates carfilzomib but not bortezomib effects on myeloma cells
- Carfilzomib: A New Proteasome Inhibitor for Treatment of Multiple Myeloma
- A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion cohort
- Overcoming Proteasome Inhibitor Resistance in Multiple Myeloma Using the XPO1: Inhibitor Selinexor